Patent application EP16201602A (EP), filed 2016-12-01
Publication number: EP3176183A1
Title: COMPOSITIONS AND METHODS FOR TREATING CANCER NOT RESISTANT TO A TYROSINE KINASE INHIBITOR (TKI)
Abstract: Compositions for use in the treatment of cancer are provided. Accordingly, there is provided tyrosine kinase inhibitor (TKI) and antibodies comprising an anti-EGFR anti body, an anti-H E R2 anti body and an anti-H E R3 anti body, for use in the treatment of cancer not resistant to a TKI.
IPC codes: A61K  33/    24            A I
A61K  39/   395            A I
A61P  35/    00            A I
C07K  16/    28            A I
C07K  16/    30            A I
C07K  16/    32            A I
Claims: number: 1
text: A tyrosine kinase inhibitor (TKI) and antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody, for use in the treatment of cancer not resistant to a TKI, wherein said TKI is directed to an ErbB family member and wherein cells of the cancer express said ErbB family member and wherein:
number: 2
text: The TKI and antibodies of claim 1, wherein said cancer is lung cancer.
number: 3
text: The TKI and antibodies of claim 2, wherein said lung cancer is a non-small cell lung cancer (NSCLC).
number: 4
text: The TKI and antibodies of any one of claims 1-3, wherein said ErbB is EGFR.
number: 5
text: The TKI and antibodies of any one of claims 1-4, wherein said TKI is AZD9291.
number: 6
text: The TKI and antibodies of any one of claims 1-5, wherein said TKI is provided below gold standard dosing as a single agent.
number: 7
text: The TKI and antibodies of any one of claims 1-5, wherein said TKI is provided at a dose that does not exert at least one side effect selected from the group consisting of skin rash, diarrhea, mouth sores, paronychia, fatigue, hyperglycemia, hepatotoxicity, kidney failure, cardiovascular effects, electrolytes anomalies and GI perforations.
Office action: search_report, dated 2017-06-07
Rejection reasons: inventive_step_epc_56
Prior art cited: ref_id: WO2012125864A2
ref_type: patent
severity: background
ref_id: US2010016296A1
ref_type: patent
severity: background
ref_id: WO2012059857A2
ref_type: patent
severity: background
ref_id: US5189178A
ref_type: patent
severity: background
ref_id: US5239078A
ref_type: patent
severity: background
ref_id: US4036945A
ref_type: patent
severity: background
ref_id: US4331647A
ref_type: patent
severity: background
ref_id: US4946778A
ref_type: patent
severity: background
ref_id: US4816567A
ref_type: patent
severity: background
ref_id: US5545807A
ref_type: patent
severity: background
ref_id: US5545806A
ref_type: patent
severity: background
ref_id: US5569825A
ref_type: patent
severity: background
ref_id: US5625126A
ref_type: patent
severity: background
ref_id: US5633425A
ref_type: patent
severity: background
ref_id: US5661016A
ref_type: patent
severity: background
ref_id: US4474893A
ref_type: patent
severity: background
ref_id: US5959084A
ref_type: patent
severity: background
ref_id: US7235641B2
ref_type: patent
severity: background
ref_id: US7183076B2
ref_type: patent
severity: background
ref_id: US2008219980A1
ref_type: patent
severity: background
ref_id: WO2010115589A1
ref_type: patent
severity: background
ref_id: WO2013150043A1
ref_type: patent
severity: background
ref_id: WO2012118903A2
ref_type: patent
severity: background
ref_id: US4666828A
ref_type: patent
severity: background
ref_id: US4683202A
ref_type: patent
severity: background
ref_id: US4801531A
ref_type: patent
severity: background
ref_id: US5192659A
ref_type: patent
severity: background
ref_id: US5272057A
ref_type: patent
severity: background
ref_id: US3791932A
ref_type: patent
severity: background
ref_id: US3839153A
ref_type: patent
severity: background
ref_id: US3850752A
ref_type: patent
severity: background
ref_id: US3850578A
ref_type: patent
severity: background
ref_id: US3853987A
ref_type: patent
severity: background
ref_id: US3867517A
ref_type: patent
severity: background
ref_id: US3879262A
ref_type: patent
severity: background
ref_id: US3901654A
ref_type: patent
severity: background
ref_id: US3935074A
ref_type: patent
severity: background
ref_id: US3984533A
ref_type: patent
severity: background
ref_id: US3996345A
ref_type: patent
severity: background
ref_id: US4034074A
ref_type: patent
severity: background
ref_id: US4098876A
ref_type: patent
severity: background
ref_id: US4879219A
ref_type: patent
severity: background
ref_id: US5011771A
ref_type: patent
severity: background
ref_id: US5281521A
ref_type: patent
severity: background
ref_id: - CITRI; Y ARDEN, NAT REV MOL CELL BIOL., vol. 7, no. 7, 2006, pages 505 - 16
ref_type: npl
severity: background
ref_id: - WANG; GREENEJ, CLIN INVEST., vol. 118, no. 7, 2008, pages 2389 - 2392
ref_type: npl
severity: background
ref_id: - WHEELER ET AL., ONCOGENE, vol. 27, no. 28, 26 June 2008 (2008-06-26), pages 3944 - 3956
ref_type: npl
severity: background
ref_id: - TAKEZAWA ET AL., CANCER DISCOVERY, vol. 2, 2012, pages 922 - 933
ref_type: npl
severity: background
ref_id: - SERGINA ET AL., NATURE, vol. 445, 2007, pages 437 - 441
ref_type: npl
severity: background
ref_id: - SARUP, MOL. CANE. T HER., vol. 7, no. 10, 2008, pages 3223 - 3236
ref_type: npl
severity: background
ref_id: - MA ET AL., MOLECULAR CANCER, vol. 13, 2014, pages 105
ref_type: npl
severity: background
ref_id: - J IANG ET AL., CHEMOTHER RES PRACT. 2012, 2012, pages 817304
ref_type: npl
severity: background
ref_id: - WHEELER ET AL., ONCOGENE, vol. 27, no. 28, 2008, pages 3944 - 3956
ref_type: npl
severity: background
ref_id: - REXER ET AL., CLIN CANCER RES., vol. 19, no. 19, 2013, pages 5390 - 401
ref_type: npl
severity: background
ref_id: - CHEN; FU, ACTA PHARMACEUTICA SINICA B, vol. 1, no. 4, 2011, pages 197 - 207
ref_type: npl
severity: background
ref_id: - KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1992, PUBLIC HEALTH SERVICE, NIH
ref_type: npl
severity: background
ref_id: - CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
ref_type: npl
severity: background
ref_id: - MARTIN ET AL., PROC. NATL ACAD SCI USA., vol. 86, 1989, pages 9268
ref_type: npl
severity: background
ref_id: - MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
ref_type: npl
severity: background
ref_id: - MAKABE ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, 2008, pages 1156 - 1166
ref_type: npl
severity: background
ref_id: - HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
ref_type: npl
severity: background
ref_id: - PORTER, R. R., BIOCHEM. J., vol. 73, 1959, pages 119 - 126
ref_type: npl
severity: background
ref_id: - INBAR ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 69, pages 2659 - 62
ref_type: npl
severity: background
ref_id: - WHITLOW; FILPULA, METHODS, vol. 2, 1991, pages 97 - 105
ref_type: npl
severity: background
ref_id: - BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
ref_type: npl
severity: background
ref_id: - PACK ET AL., BIO/TECHNOLOGY, vol. 11, 1993, pages 1271 - 77
ref_type: npl
severity: background
ref_id: - LARRICK; FRY, METHODS, vol. 2, 1991, pages 106 - 10
ref_type: npl
severity: background
ref_id: - JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
ref_type: npl
severity: background
ref_id: - RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ref_type: npl
severity: background
ref_id: - PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
ref_type: npl
severity: background
ref_id: - RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
ref_type: npl
severity: background
ref_id: - VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
ref_type: npl
severity: background
ref_id: - HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1991, pages 381
ref_type: npl
severity: background
ref_id: - MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581
ref_type: npl
severity: background
ref_id: - COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, pages: 77
ref_type: npl
severity: background
ref_id: - BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95
ref_type: npl
severity: background
ref_id: - MARKS ET AL.: "Bio/Technology", vol. 10, 1992, SCIENTIFIC PUBLICATIONS, pages: 779 - 783
ref_type: npl
severity: background
ref_id: - LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859
ref_type: npl
severity: background
ref_id: - MORRISON, NATURE, vol. 368, 1994, pages 812 - 13
ref_type: npl
severity: background
ref_id: - FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 51
ref_type: npl
severity: background
ref_id: - NEUBERGER, NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 826
ref_type: npl
severity: background
ref_id: - LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93
ref_type: npl
severity: background
ref_id: - BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
ref_type: npl
severity: background
ref_id: - RASO ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 27623
ref_type: npl
severity: background
ref_id: - "Remington's Pharmaceutical Sciences", MACK PUBLISHING CO.
ref_type: npl
severity: background
ref_id: - FINGL E. ET AL.: "The Pharmacological Basis of Therapeutics", 1975, pages: 1
ref_type: npl
severity: background
ref_id: - REGALES ET AL., PLOS ONE, vol. 2, 2007, pages E810
ref_type: npl
severity: background
ref_id: - POLITI ET AL., GENES DEV., vol. 20, 2006, pages 1496 - 1510
ref_type: npl
severity: background
ref_id: - SAMBROOK ET AL.: "Molecular Cloning: A laboratory Manual", 1989
ref_type: npl
severity: background
ref_id: - "Current Protocols in Molecular Biology", vol. I-III, 1994
ref_type: npl
severity: background
ref_id: - AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1989, JOHN WILEY AND SONS
ref_type: npl
severity: background
ref_id: - PERBAL: "A Practical Guide to Molecular Cloning", 1988, JOHN WILEY & SONS
ref_type: npl
severity: background
ref_id: - WATSON ET AL.: "Recombinant DNA", SCIENTIFIC AMERICAN BOOKS
ref_type: npl
severity: background
ref_id: - "Genome Analysis: A Laboratory Manual Series", vol. 1-4, 1998, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: - "Cell Biology: A Laboratory Handbook", 1994, I-III
ref_type: npl
severity: background
ref_id: - FRESHNEY: "Culture of Animal Cells - A Manual of Basic Technique", 1994, WILEY-LISS
ref_type: npl
severity: background
ref_id: - "Current Protocols in Immunology", vol. I-III, 1994
ref_type: npl
severity: background
ref_id: - "Basic and Clinical Immunology", 1994, APPLETON & LANGE
ref_type: npl
severity: background
ref_id: - "Selected Methods in Cellular Immunology", 1980, W. H. FREEMAN AND CO.
ref_type: npl
severity: background
ref_id: - "Oligonucleotide Synthesis", 1984
ref_type: npl
severity: background
ref_id: - "Nucleic Acid Hybridization", 1985
ref_type: npl
severity: background
ref_id: - "Transcription and Translation", 1984
ref_type: npl
severity: background
ref_id: - "Animal Cell Culture", 1986
ref_type: npl
severity: background
ref_id: - "Immobilized Cells and Enzymes", 1986, IRL PRESS
ref_type: npl
severity: background
ref_id: - PERBAL, B.: "A Practical Guide to Molecular Cloning", 1984
ref_type: npl
severity: background
ref_id: - "Methods in Enzymology", vol. 1-317, ACADEMIC PRESS
ref_type: npl
severity: background
ref_id: - "PCR Protocols: A Guide To Methods And Applications", 1990, ACADEMIC PRESS
ref_type: npl
severity: background
ref_id: - MARSHAK ET AL.: "Strategies for Protein Purification and Characterization - A Laboratory Course Manual", 1996, CSHL PRESS
ref_type: npl
severity: background
ref_id: - FRIEDMAN ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, 2005, pages 1915 - 1920
ref_type: npl
severity: background
ref_id: - KLAPPER ET AL., ONCOGENE, vol. 14, 1997, pages 2099 - 2109
ref_type: npl
severity: background
ref_id: - CHEN ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, 1996, pages 7620 - 7629
ref_type: npl
severity: background
ref_id: - CHEN ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 13, 1996, pages 7620 - 762
ref_type: npl
severity: background
ref_id: - LIAO ET AL., CURRENT OPINION ONCOLOGY, 2015
ref_type: npl
severity: background
ref_id: - THRESS ET AL.: "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M", NATURE MEDICINE, vol. 21, 2015, pages 560 - 562
ref_type: npl
severity: background
ref_id: - R. SIEGEL; J. M A, Z. ZOU; A. J EMAL: "Cancer statistics", CA: A CANCER JOURNAL FOR CLINICIANS, vol. 64, January 2014 (2014-01-01), pages 9 - 29, XP055320560, DOI: doi:10.3322/caac.21208
ref_type: npl
severity: background
ref_id: - T.J. LYNCH; D. W. BELL; R. SORDELLA; S. GURUBHAGAVATULA; R. A. OKIMOTO; B. W. BRANNIGAN; P. L. HARRIS; S. M. HASERLAT; J. G. SUPKO: "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 350, 20 May 2004 (2004-05-20), pages 2129 - 2139, XP002447439, DOI: doi:10.1056/NEJMoa040938
ref_type: npl
severity: background
ref_id: - J. G. PAEZ; P. A. JANNE; J. C. LEE; S. TRACY; H. GREULICH; S. GABRIEL; P. HERMAN; F.J. KAYE; N. LINDEMAN; T.J. BOGGON: "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", SCIENCE, vol. 304, 4 June 2004 (2004-06-04), pages 1497 - 1500, XP002359959, DOI: doi:10.1126/science.1099314
ref_type: npl
severity: background
ref_id: - W. PAO; V. MILLER; M. ZAKOWSKI; J. DOHERTY; K. POLITI; I. SARKARIA; B. SINGH; R. HEELAN; V. RUSCH; L. FULTON: "EGF receptor gene mutati ons are common in lung cancers from ''never smokers'' and are associated with sensitivity of tumors to gefitinib and erlotinib", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, 7 September 2004 (2004-09-07), pages 13306 - 13311
ref_type: npl
severity: background
ref_id: - Y. YARDEN; G. PINES: "The ERBB network: at last, cancer therapy meets systems biology", NATURE REVIEWS. CANCER, vol. 12, August 2012 (2012-08-01), pages 553 - 563
ref_type: npl
severity: background
ref_id: - T. S. MOK; Y. L. WU; S. THONGPRASERT; C. H. YANG; D. T. CHU; N. SAIJO; P. SUNPAWERAVONG; B. HAN; B. MARGONO; Y. ICHINOSE: "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, 3 September 2009 (2009-09-03), pages 947 - 957, XP055073586, DOI: doi:10.1056/NEJMoa0810699
ref_type: npl
severity: background
ref_id: - R. ROSELL; T. MORAN; C. QUERALT; R. PORTA; F. CARDENAL; C. CAMPS; M. MAJEM; G. LOPEZ-V IVANCO; D. ISLA; M. PROVENCIO: "Lung Cancer, Screening for epidermal growth factor receptor mutations in lung cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, 3 September 2009 (2009-09-03), pages 958 - 967, XP002664831, DOI: doi:10.1056/NEJMoa0904554
ref_type: npl
severity: background
ref_id: - G. R. OXNARD; M. E. ARCILA; J. CHMIELECKI; M. LADANYI; V. A. MILLER; W. PAO: "New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 17, 1 September 2011 (2011-09-01), pages 5530 - 5537
ref_type: npl
severity: background
ref_id: - W. PAO; V. A. MILLER; K. A. POLITI; G.J. RIELY; R. SOMWAR; M. F. ZAKOWSKI; M. G. K RIS; H. V ARMUS: "Acqui red resistance of lung adenocarci nomas to gefiti ni b or erlotinib is associated with a second mutation in the EGFR kinase domain", PLOS MEDICINE, vol. 2, March 2005 (2005-03-01), pages E73
ref_type: npl
severity: background
ref_id: - S. KOBAYASHI; T.J. BOGGON; T. DAYARAM; P.A.JANNE; O. KOCHER; M. MEYERSON; B. E. JOHNSON; M. J. ECK; D. G. TENEN; B. HALMOS: "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 352, 24 February 2005 (2005-02-24), pages 786 - 792, XP002395764
ref_type: npl
severity: background
ref_id: - J. A. ENGELMAN; K. ZEJNULLAHU; T. MITSUDOMI; Y. SONG; C. HYLAND; J. O. PARK; N. LINDEMAN; C. M. GALE; X. ZHAO; J. CHRISTENSEN: "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling", SCIENCE, vol. 316, 18 May 2007 (2007-05-18), pages 1039 - 1043, XP002498405, DOI: doi:10.1126/science.1141478
ref_type: npl
severity: background
ref_id: - J. BEAN; C. BRENNAN; J. Y. SHIH; G. RIELY; A. VIALE; L. WANG; D. CHITALE; N. MOTOI; J. SZOKE; S. BRODERICK: "MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, 26 December 2007 (2007-12-26), pages 20932 - 20937, XP002566375, DOI: doi:10.1073/PNAS.0710370104
ref_type: npl
severity: background
ref_id: - K. OHASHI; Y. E. MARUVKA; F. MICHOR; W. PAO: "Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease", JOURNAL OF CLINICAL ONCOLOGY: OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 31, 10 March 2013 (2013-03-10), pages 1070 - 1080
ref_type: npl
severity: background
ref_id: - F. R. HIRSCH; P. A. J ANNE; W. E. EBERHARDT; F. CAPPUZZO; N. THATCHER; R. PIRKER; H. CHOY; E. S. KIM; L. PAZ-ARES; D. R. GANDARA: "Epidermal growth factor receptor inhibition in lung cancer: status 2012", JOURNAL OF THORACIC ONCOLOGY: OFFICIAL PUBLICATION OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, vol. 8, 2013, pages 373 - 384
ref_type: npl
severity: background
ref_id: - R. PIRKER; J. R. PEREIRA; A. SZCZESNA; J. VON PAWEL; M. KRZAKOWSKI; I. VYNNYCHENKO; K. PARK; C. T. Y U; V. GANUL; J. K. ROH: "Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial", LANCET, vol. 373, 2 May 2009 (2009-05-02), pages 1525 - 1531, XP026088699, DOI: doi:10.1016/S0140-6736(09)60569-9
ref_type: npl
severity: background
ref_id: - E. C. DE BRUIN; C. COWELL; P. H. WARNE; M. JIANG; R. E. SAUNDERS; M. A. MELNICK; S. GETTINGER; Z. WALTHER; A. WURTZ; G. J. HEYNEN: "Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer", CANCER DISCOVERY, vol. 4, May 2014 (2014-05-01), pages 606 - 619
ref_type: npl
severity: background
ref_id: - J. CHO; L. CHEN; N. SANGJI; T. OKABE; K. YONESAKA; J. M. FRANCIS; R.J. FLAVIN; W.JOHNSON; J. KWON; S.YU: "Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization", CANCER RESEARCH, vol. 73, 15 November 2013 (2013-11-15), pages 6770 - 6779
ref_type: npl
severity: background
ref_id: - R. MARON; B. SCHECHTER; M. MANCINI; G. MAHLKNECHT; Y. YARDEN; M. SELA: "Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, 17 September 2013 (2013-09-17), pages 15389 - 15394
ref_type: npl
severity: background
ref_id: - D. A. FERRARO; N. GABORIT; R. MARON; H. COHEN-DVASHI; Z. PORAT; F. PAREJA; S. LAVI; M. LINDZEN; N. BEN-CHETRIT; M. SELA: "Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR", PROCEEDINGS OF THE NATIONAL ACADENY OF SCIENCES OF THE UNITED STATES OF AMERICA, 14 January 2013 (2013-01-14)
ref_type: npl
severity: background
ref_id: - V. SERRA; M. SCALTRITI; L. PRUDKIN; P. J. EICHHORN; Y. H. IBRAHIM; S. CHANDARLAPATY; B. MARKMAN; O. RODRIGUEZ; M. GUZMAN; S. RODRI: "PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer", ONCOGENE, vol. 30, 2 June 2011 (2011-06-02), pages 2547 - 2557, XP055197081, DOI: doi:10.1038/onc.2010.626
ref_type: npl
severity: background
ref_id: - I. AMIT; R. WIDES; Y. Y ARDEN: "Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy", MOL SYST BIOL, vol. 3, 2007, pages 151
ref_type: npl
severity: background
ref_id: - B. N. KHOLODENKO; J. F. HANCOCK; W. KOLCH: "Signalling ballet in space and time", NAT REV MOL CELL BIOL, vol. 11, June 2010 (2010-06-01), pages 414 - 426
ref_type: npl
severity: background
ref_id: - N. V. SERGINA; M. RAUSCH; D. WANG; J. BLAIR; B. HANN; K. M. SHOKAT; M. M. MOASSER: "Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3", NATURE, vol. 445, 25 January 2007 (2007-01-25), pages 437 - 441, XP002548476, DOI: doi:10.1038/NATURE05474
ref_type: npl
severity: background
ref_id: - C. MONTERO-CONDE; S. RUIZ-LLORENTE; J. M. DOMINGUEZ; J. A. KNAUF; A. VIALE; E. J. SHERMAN; M. RYDER; R. A. GHOSSEIN; N. ROSEN; J.: "Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas", CANCER DISCOVERY, vol. 3, May 2013 (2013-05-01), pages 520 - 533
ref_type: npl
severity: background
ref_id: - K. TAKEZAWA; V. PIRAZZOLI; M. E. ARCILA; C. A. NEBHAN; X. SONG; E. DE STANCHINA; K. OHASHI; Y. Y. J ANJIGIAN; P. J. SPITZLER; M. A: "HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation", CANCER DISCOVERY, vol. 2, October 2012 (2012-10-01), pages 922 - 933
ref_type: npl
severity: background
ref_id: - K. SHTIEGMAN; B. S. KOCHUPURAKKAL; Y. ZWANG; G. PINES; A. STARR; A. VEXLER; A. CITRI; M. KATZ; S. LAVI; Y. BEN-BASAT: "Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling", ONCOGENE, vol. 26, 25 October 2007 (2007-10-25), pages 6968 - 6978
ref_type: npl
severity: background
ref_id: - J. L. PUJOL; R. PIRKER; T. J. LYNCH; C. A. BUTTS; R. ROSELL; F. A. SHEPHERD; J. VANSTEENKISTE; K.J. O'BYRNE; B. DE BLAS; J. HEIGHW: "Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer", LUNG CANCER, vol. 83, February 2014 (2014-02-01), pages 211 - 218
ref_type: npl
severity: background
ref_id: - J. C. YANG; V. HIRSH; M. SCHULER; N. YAMAMOTO; K.J. O'BYRNE; T. S. MOK; V. ZAZULINA; M. SHAHIDI; J. LUNGERSHAUSEN; D. MASSEY: "Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 31, 20 September 2013 (2013-09-20), pages 3342 - 3350
ref_type: npl
severity: background
ref_id: - J. BASELGA; J. CORTES; S. B. KIM; S. A. IM; R. HEGG; Y. H. IM; L. ROMAN; J. L. PEDRINI; T. PIENKOWSKI; A. KNOTT: "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 366, 12 January 2012 (2012-01-12), pages 109 - 119, XP055057318, DOI: doi:10.1056/NEJMoa1113216
ref_type: npl
severity: background
ref_id: WO2012125864A2
ref_type: patent
severity: background
ref_id: WO2012156975A1
ref_type: patent
severity: background
ref_id: WO2012125864
ref_type: patent
severity: obviousness
ref_id: WO2012156975
ref_type: patent
severity: obviousness
Final disposition: pending (2017-06-07)